PREVIOUS
✖
First Pediatric IBS-C Drug - Linzess
November 11 , 2025
16 hrs 0 min
13
0
- The USFDA has approved Linzess (Linaclotide) for children aged seven years and older with irritable bowel syndrome with constipation (IBS-C).
- This marks the first FDA-approved treatment for paediatric patients with IBS-C.
- Linzess improves bowel movement frequency and reduces abdominal pain in affected children.
- Linzess is not approved for children under two years of age due to the risk of severe dehydration.
Leave a Reply
Your Comment is awaiting moderation.